iSpecimen (ISPC)
NASDAQ:ISPC
Want to see ISPC full AI Analyst Report?
Top Page
iSpecimen
(NASDAQ:ISPC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.00
▲(1190.32% Upside)
Action:ReiteratedDate:04/30/26
The score is weighed down primarily by very weak financial performance (sharp revenue contraction, margin collapse, large losses, and ongoing cash burn). Technicals add downside pressure with a clear downtrend and negative momentum indicators. Valuation provides limited support because the negative P/E reflects unprofitability and there is no dividend yield data.
Positive Factors
Improved global logistics and faster delivery
Direct shipment and a reduced multi-step routing model materially shorten transit times and lower shipping costs. Structurally faster, cheaper logistics strengthen customer value proposition, expand addressable markets (including international and rare specimens), and improve long-term supplier and buyer retention.
Negative Factors
Severe revenue contraction
A persistent and large revenue decline signals structural demand loss or competitive displacement. Over multiple years this erodes scale, reduces network effects in a marketplace model, and makes it harder to cover fixed costs, hindering sustainable recovery without clear new revenue drivers.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved global logistics and faster delivery
Direct shipment and a reduced multi-step routing model materially shorten transit times and lower shipping costs. Structurally faster, cheaper logistics strengthen customer value proposition, expand addressable markets (including international and rare specimens), and improve long-term supplier and buyer retention.
Read all positive factors
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.62M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth-79.24%
EPS Growth88.08%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,316,032
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)15.50
Price to Sales (P/S)24.81
P/FCF Ratio-11.29
Enterprise Value/Market Cap-1.07
Enterprise Value/Revenue-3.12
Enterprise Value/Gross Profit-249.65
Enterprise Value/Ebitda0.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iSpecimen Business Overview & Revenue Model
Company Description
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology...
How the Company Makes Money
iSpecimen primarily makes money by facilitating transactions on its marketplace between biospecimen buyers (e.g., pharmaceutical/biotech companies, diagnostics developers, academic and clinical researchers, and other research organizations) and bi...
iSpecimen Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.93M | 9.29M | 9.93M | 10.40M | 11.14M |
| Gross Profit | 24.11K | 3.99M | 5.11M | 5.65M | 5.89M |
| EBITDA | -8.75M | -12.73M | -8.80M | -8.80M | -5.86M |
| Net Income | -10.49M | -12.50M | -11.10M | -10.25M | -8.96M |
Balance Sheet | |||||
| Total Assets | 9.53M | 9.35M | 15.82M | 24.62M | 35.72M |
| Cash, Cash Equivalents and Short-Term Investments | 6.88M | 1.88M | 5.01M | 15.31M | 27.74M |
| Total Debt | 268.80K | 312.17K | 196.24K | 185.85K | 3.42M |
| Total Liabilities | 6.44M | 6.04M | 6.08M | 4.31M | 5.93M |
| Stockholders Equity | 3.09M | 3.31M | 9.74M | 20.31M | 29.79M |
Cash Flow | |||||
| Free Cash Flow | -4.24M | -8.30M | -10.55M | -9.01M | -11.71M |
| Operating Cash Flow | -4.24M | -8.26M | -5.81M | -5.82M | -10.67M |
| Investing Cash Flow | -1.00M | 1.98M | -7.23M | -3.19M | -1.04M |
| Financing Cash Flow | 10.24M | 5.82M | 70.89K | -3.42M | 38.75M |
iSpecimen Technical Analysis
Negative
0.31
Price Trends
0.22
Negative
0.30
Negative
0.67
Negative
Market Momentum
-0.03
Negative
42.34
Neutral
23.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.31 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.22, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.34 is Neutral, neither overbought nor oversold. The STOCH value of 23.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.
iSpecimen Risk Analysis
iSpecimen disclosed 72 risk factors in its most recent earnings report. iSpecimen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
iSpecimen Peers Comparison
UnderperformOutperform
Sector (51)
ISPC
iSpecimen
4.27
-46.93
-91.66%
INBS
Intelligent Bio Solutions
2.35
-11.16
-82.63%
BGLC
BioNexus Gene Lab Corp
2.06
-0.73
-26.16%
BIAF
bioAffinity Technologies, Inc.
2.43
-11.82
-82.95%
iSpecimen Corporate Events
Shareholder Meetings
iSpecimen Reschedules Annual Meeting Amid Ongoing Quorum Challenges
Negative
Apr 13, 2026
iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders on December 31, 2025, but repeatedly lacked a quorum, forcing adjournments on January 23, February 13, March 13, and April 10, 2026. The company plans to reconvene the meeting on May ...
Business Operations and StrategyProduct-Related Announcements
iSpecimen Unveils Streamlined Global Shipping for Biospecimens
Positive
Apr 10, 2026
On April 9, 2026, iSpecimen announced it has implemented a streamlined shipping model that enables direct shipment of human biospecimens from supplier sites to customers in domestic and international markets. By reducing reliance on central hub pr...
Business Operations and StrategyShareholder Meetings
iSpecimen Faces Ongoing Shareholder Quorum Challenges for Meeting
Negative
Mar 13, 2026
On December 31, 2025, iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders but adjourned it due to a lack of quorum, a problem that recurred when the meeting was reconvened on January 23, 2026, February 13, 2026, and March 13, 2026. The...
Shareholder Meetings
iSpecimen Faces Ongoing Annual Meeting Quorum Challenges
Negative
Feb 18, 2026
On December 31, 2025, iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders but adjourned it after failing to reach a quorum, preventing votes on the proposals outlined in its November 21, 2025 proxy materials. The meeting was reconvened...
Business Operations and StrategyProduct-Related Announcements
iSpecimen Advances Digital Marketplace with SalesStack Milestone
Positive
Feb 6, 2026
On February 6, 2026, iSpecimen announced it had successfully completed Milestone 2 of its SalesStack digital transformation program, delivering full system integration and activating a live production marketplace that links customer requests with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.